Has the CSL share price got further to fall?

ASX experts weigh in on what's next for CSL.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Well, things were looking up for the CSL Ltd (ASX: CSL) share price. Until 12 February earlier this month, that is. 

Between late October and 12 February, CSL shares were on a tear. This ASX 200 healthcare stock rose more than 32% between those two dates. But after the company released some bitterly disappointing test results for a new cardiovascular drug, investors lost a lot of their confidence.

Since 12 February, CSL shares have tanked by more than 6.6%, falling from over $300 each to the $285.50 we see today (at market close).

Not even a confident earnings report earlier this month could restore investor enthusiasm. As we covered at the time, those earnings revealed that CSL was able to record an 11% rise in revenues, as well as a 20% increase in net profits for the six months ending 31 December. Investors were also treated to a 12% dividend pay rise.

Check out the CSL share price's movements below for yourself:

So with CSL shares coming off the boil and seemingly not getting back on, ASX investors might be asking themselves whether CSL shares have further to fall. After all, it was only in late October that this healthcare giant got as low as $228.65 a share.

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.

Image source: Getty Images

Does the CSL share price have further to fall?

Well, let's see what some ASX experts think.

Following the release of CSL's earnings, my Fool colleague James covered the views of ASX broker Morgans. Morgans did trim its price target for CSL shares following its disappointing trial results. But it still rates the company as an add following its earnings, with a price target of $315.40. If realised, that would represent an upside of more than 10% from current prices.

Morgans was happy with what CSL reported earlier this month and evidently sees significant value in the company's share price at its current levels.

But Morgans isn't the only expert that is eyeing off the healthcare giant right now. eToro analyst Josh Gilbert shares a positive view. Here's some of what he recently said about CSL right now:

CSL shareholders will have reason to smile today with the release of a solid half-yearly report… [These] results show that the business continues to move in the right direction, and there is plenty to be positive about. With solid profit growth, a healthy dividend, solid guidance, and interest rate cuts not far away, CSL will be on investors' watchlists.

So it appears that at least two ASX experts reckon CSL shares are more likely to head up than down going forward. But, as always, we'll have to wait and see if that turns out to be the case.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

PolyNovo FY26 earnings: Record revenue and cash flow

PolyNovo posts record group revenue, robust cash flow, and surging commercial sales for FY26, with a positive outlook for further…

Read more »

A man rests his chin in his hands, pondering what is the answer?
Healthcare Shares

Down 55% in a year: Do brokers still rate CSL shares as a buy?

Is there any sign of a turnaround coming?

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

3 reasons why this ASX healthcare share price is a buy

This ASX healthcare share has a very positive outlook.

Read more »

An older woman tries to listen by cupping her ear.
Healthcare Shares

How many Cochlear shares do I need to buy for $10,000 of passive income?

The dividend maths on this fallen ASX healthcare heavyweight.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Broker Notes

Are Telix shares a buy, hold or sell following results?

This exciting healthcare stock is tipped to keep rising.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 53%, here's why this ASX All Ords healthcare share is tipped for more outperformance

A leading fund manager forecasts more outperformance from this surging ASX healthcare share.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 79% since February, why are Telix shares jumping higher again on Tuesday?

Investors are piling into Telix shares in Tuesday’s slumping market. But why?

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Top 3 ASX healthcare stocks to watch

Three beaten-down ASX healthcare stocks staging a strong comeback.

Read more »